重新审视HER2阴性原发性乳腺癌的雌激素受体阳性定义
该研究纳入1982年6月至2013年6月间接受新辅助化疗后根治性手术的II或III期HER2阴性原发性乳腺癌患者3055例,分析ER表达百分比与病理完全缓解(pCR)及辅助内分泌治疗获益的关系。结果显示ER低表达与高pCR率显著相关(OR=0.99,95%CI=0.986-0.994,P<0.001),推荐预测pCR可能的ER临界值为9.5%。在ER≥10%肿瘤中,辅助内分泌治疗与无复发生存(HR=0.24,95%CI=0.16-0.36,P<0.001)和总生存(HR=0.32,95%CI=0.2-0.5,P<0.001)显著相关,而1%≤ER<10%肿瘤中未见此关联。结论认为ER<10%的HER2阴性乳腺癌在pCR和生存结局上临床行为类似三阴性乳腺癌,辅助内分泌治疗获益可能有限。
要点
- ER低表达与高pCR率显著相关(OR=0.99,95%CI=0.986-0.994,P<0.001)。
- 推荐ER表达低于9.5%时pCR可能。
- ER≥10%肿瘤中辅助内分泌治疗与无复发生存(HR=0.24)和总生存(HR=0.32)显著相关。
核心结论
- II或III期HER2阴性原发性乳腺癌ER<10%在pCR和生存结局上临床行为类似三阴性乳腺癌,辅助内分泌治疗获益可能有限。
- 将三阴性乳腺癌定义为HER2阴性且ER和/或孕激素受体表达<10%而非<1%可能更具临床相关性。
研究设计与样本
- 纳入1982年6月至2013年6月间接受新辅助化疗后根治性手术的II或III期HER2阴性原发性乳腺癌患者3055例。
- 采用逻辑回归模型评估变量与pCR的关联,Cox模型分析复发时间和总生存,递归分割与回归树法计算ER表达临界值。
主要发现
- ER低百分比与高pCR率显著相关(OR=0.99,95%CI=0.986-0.994,P<0.001)。
- 推荐预测pCR可能的ER表达临界值为9.5%。
- ER≥10%肿瘤中辅助内分泌治疗与较长复发时间(HR=0.24,95%CI=0.16-0.36,P<0.001)和总生存(HR=0.32,95%CI=0.2-0.5,P<0.001)显著相关。
- 1%≤ER<10%肿瘤中辅助内分泌治疗与复发时间和总生存无显著关联。
关键数值与推荐
- ER低百分比与高pCR率相关(OR=0.99,95%CI=0.986-0.994,P<0.001)。
- 预测pCR可能的推荐ER临界值为9.5%。
- ER≥10%肿瘤中辅助内分泌治疗与无复发生存相关(HR=0.24,95%CI=0.16-0.36,P<0.001)。
- ER≥10%肿瘤中辅助内分泌治疗与总生存相关(HR=0.32,95%CI=0.2-0.5,P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although 1% has been used as cut-off for estrogen receptor (ER) positivity, several studies have reported that tumors with ER < 1% have characteristics similar to those with 1% ≤ ER < 10%. We hypothesized that in patients with human epidermal growth factor 2 (HER2)-negative breast cancer, a cut-off of 10% is more useful than one of 1% in discriminating for both a better pathological complete response (pCR) rate to neoadjuvant chemotherapy and a better long-term outcome with adjuvant hormonal therapy. Our objectives were to identify a percentage of ER expression below which pCR was likely and to determine whether this cut-off value can identify patients who would benefit from adjuvant hormonal therapy. PATIENTS AND METHODS: Patients with stage II or III HER2-negative primary breast cancer who received neoadjuvant chemotherapy followed by definitive surgery between June 1982 and June 2013 were included. Logistic regression models were used to assess the association between each variable and pCR. Cox models were used to analyze time to recurrence and overall survival. The recursive partitioning and regression trees method was used to calculate the cut-off value of ER expression. RESULTS: A total of 3055 patients were analyzed. Low percentage of ER was significantly associated with high pCR rate (OR = 0.99, 95% CI = 0.986-0.994, P < 0.001). The recommended cut-off of ER expression below which pCR was likely was 9.5%. Among patients with ER ≥ 10% tumors, but not those with 1%≤ER < 10% tumors, adjuvant hormonal therapy was significantly associated with long time to recurrence (HR = 0.24, 95% CI = 0.16-0.36, P < 0.001) and overall survival (HR = 0.32, 95% CI = 0.2-0.5, P < 0.001). CONCLUSION: Stage II or III HER2-negative primary breast cancer with ER < 10% behaves clinically like triple-negative breast cancer in terms of pCR and survival outcomes and patients with such tumors may have a limited benefit from adjuvant hormonal therapy. It may be more clinically relevant to define triple-negative breast cancer as HER2-negative breast cancer with <10%, rather than <1%, of ER and/or progesterone receptor expression.
引用
- Fujii T, Kogawa T, Dong W, et al. Revisiting the definition of estrogen receptor positivity in HER2-negative primary breast cancer. Ann Oncol. 2017. PMID: 28961844. doi:10.1093/annonc/mdx397
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。